Isolated pathogens in infectious disease episodes after lymphodepletion in 14 patients undergoing CAR19 T-cell therapy
| Documented infection, n (%) . | ≤30 d after CAR-T infusion (n = 18), n (%) . | >30 d after CAR-T infusion (n = 15), n (%) . |
|---|---|---|
| Bacterial | 9 (50) | 4 (26.6) |
| BSI | ||
| Escherichia coli | 1 (5.5) | 1 (6) |
| Klebsiella pneumoniae | 1 (5.5) | |
| Staphylococcus epidermidis | 1 (5.5) | |
| Bacteroides fragilis | 1 (5.5) | |
| Staphylococcus aureus | 1 (5.5) | |
| Diarrhea | ||
| E coli, enteroaggregative | 1 (5.5) | |
| Clostridium difficile | 3 (16.6) | |
| Respiratory | ||
| Mycoplasma pneumoniae | 1 (6) | |
| S aureus | 1 (6) | |
| CNS, M tuberculosis∗ | 1† (6) | |
| Viral | 4 (22.2) | 9 (60) |
| Respiratory | ||
| Parainfluenza | 3 (20) | |
| Enterovirus | 1 (6) | |
| Rhinovirus | 1 (5.5) | 3 (20) |
| SARS-CoV-2 | 1 (6) | |
| BSI, CMV, CSCMVi | 3 (16.6) | |
| Diarrhea, norovirus | 1 (6) | |
| Fungi | 4 (22.2) | 2 (13.3) |
| BSI | ||
| Candida tropicalis | 1 (5.5) | |
| Candida krusei | 1‡ (5.5) a | |
| Respiratory, probable aspergillosis | 1 (5.5) | 2 (13.3) |
| Skin, Cryptococcus sp.∗ | 1 (5.5) | |
| Protozoan, Diarrhea, Giardia lamblia∗ | 1 (5.5) | |
| Total documented infection | 18 | 15 |
| Fever, febrile neutropenia without isolated germ/CRS | 6/23 (26) |
| Documented infection, n (%) . | ≤30 d after CAR-T infusion (n = 18), n (%) . | >30 d after CAR-T infusion (n = 15), n (%) . |
|---|---|---|
| Bacterial | 9 (50) | 4 (26.6) |
| BSI | ||
| Escherichia coli | 1 (5.5) | 1 (6) |
| Klebsiella pneumoniae | 1 (5.5) | |
| Staphylococcus epidermidis | 1 (5.5) | |
| Bacteroides fragilis | 1 (5.5) | |
| Staphylococcus aureus | 1 (5.5) | |
| Diarrhea | ||
| E coli, enteroaggregative | 1 (5.5) | |
| Clostridium difficile | 3 (16.6) | |
| Respiratory | ||
| Mycoplasma pneumoniae | 1 (6) | |
| S aureus | 1 (6) | |
| CNS, M tuberculosis∗ | 1† (6) | |
| Viral | 4 (22.2) | 9 (60) |
| Respiratory | ||
| Parainfluenza | 3 (20) | |
| Enterovirus | 1 (6) | |
| Rhinovirus | 1 (5.5) | 3 (20) |
| SARS-CoV-2 | 1 (6) | |
| BSI, CMV, CSCMVi | 3 (16.6) | |
| Diarrhea, norovirus | 1 (6) | |
| Fungi | 4 (22.2) | 2 (13.3) |
| BSI | ||
| Candida tropicalis | 1 (5.5) | |
| Candida krusei | 1‡ (5.5) a | |
| Respiratory, probable aspergillosis | 1 (5.5) | 2 (13.3) |
| Skin, Cryptococcus sp.∗ | 1 (5.5) | |
| Protozoan, Diarrhea, Giardia lamblia∗ | 1 (5.5) | |
| Total documented infection | 18 | 15 |
| Fever, febrile neutropenia without isolated germ/CRS | 6/23 (26) |
CSCMVi represents CMV disease or CMV viremia leading to preemptive treatment.
BSI, bloodstream infection; CSCMVi, clinically significant CMV infection.
Endemic pathogens.
This patient had concomitant tuberculosis pulmonary and CNS infection.
This patient showed positive blood culture and urine culture for C krusei.